Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NAMS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's… NCT07794670 · Preclinical Alzheimer's Disease Obicetrapib 10 mg, Matching placebo tablets | NAMS NewAmsterdam Pharma | Phase 2 | Recruiting | 400 | Sep 2028 | Registry ↗ |
| Sep 9, 2026 | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib… NCT07219602 · Lipidemia, Type 2 Diabetes (T2DM) obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib… | NAMS NewAmsterdam Pharma | Phase 3 | Active, not recruiting | 300 | Mar 2028 | Registry ↗ |
| Apr 9, 2026 | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels NCT06496243 · Dyslipidemias obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks | NAMS NewAmsterdam Pharma | Phase 2 | Recruiting | 69 | Nov 2026 | Registry ↗ |
| Apr 9, 2026 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque NCT06305559 · Lipidemia, Coronary Artery Disease obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Placebo | NAMS NewAmsterdam Pharma | Phase 3 | Active, not recruiting | 300 | Nov 2027 | Registry ↗ |
| Oct 20, 2025 | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers NCT06982508 · Antioxidant Absorption Obicetrapib 10mg, Placebo | NAMS NewAmsterdam Pharma | Phase 2 | Recruiting | 100 | Sep 2026 | Registry ↗ |
| Oct 8, 2025 | Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying… NCT06005597 · Dyslipidemias, Hypercholesterolemia Combination Therapy, Monotherapy obicetrapib | NAMS NewAmsterdam Pharma | Phase 3 | Completed | 407 | Sep 25, 2024 | Registry ↗ |
| Sep 19, 2025 | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying… NCT05142722 · Dyslipidemias, High Cholesterol Placebo, Obicetrapib | NAMS NewAmsterdam Pharma | Phase 3 | Completed | 2,530 | Sep 26, 2024 | Registry ↗ |
| Jun 11, 2025 | Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifyin… NCT05425745 · Dyslipidemias, High Cholesterol Obicetrapib, Placebo | NAMS NewAmsterdam Pharma | Phase 3 | Completed | 354 | May 28, 2024 | Registry ↗ |
| May 22, 2025 | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvast… NCT06081166 · Healthy Volunteers Obicetrapib, Atorvastatin Calcium | NAMS NewAmsterdam Pharma | Phase 1 | Completed | 74 | Dec 2, 2023 | Registry ↗ |
| Jan 29, 2025 | Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease NCT05161715 · Early Alzheimer's Disease Obicetrapib | NAMS NewAmsterdam Pharma | Phase 2 | Completed | 13 | May 9, 2023 | Registry ↗ |
| Nov 14, 2024 | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy… NCT06547359 · Healthy Volunteers Obicetrapib 10mg, Ezetimibe 10mg | NAMS NewAmsterdam Pharma | Phase 1 | Completed | 94 | Nov 12, 2024 | Registry ↗ |
| Oct 29, 2024 | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to St… NCT05421078 · Dyslipidemia, Hypercholesterolemia Obicetrapib, Placebo | NAMS NewAmsterdam Pharma | Phase 2 | Completed | 102 | Mar 24, 2023 | Registry ↗ |
| Sep 19, 2024 | Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib NCT06250205 · Healthy Volunteers Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol… | NAMS NewAmsterdam Pharma | Phase 1 | Completed | 30 | Apr 25, 2024 | Registry ↗ |
| Sep 19, 2024 | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Norma… NCT06048302 · Hepatic Impairment, Healthy Obicetrapib | NAMS NewAmsterdam Pharma | Phase 1 | Completed | 18 | Mar 12, 2024 | Registry ↗ |
| Sep 19, 2024 | Investigating the Effect of Obicetrapib on Lipoprotein Metabolism NCT05972278 · Lipid Metabolism Obicetrapib | NAMS NewAmsterdam Pharma | Phase 1 | Unknown | 22 | Sep 26, 2024 | Registry ↗ |
| Jul 12, 2024 | Randomized Study of Obicetrapib as an Adjunct to Statin Therapy NCT04753606 · Dyslipidemias, High Cholesterol Obicetrapib | NAMS NewAmsterdam Pharma | Phase 2 | Completed | 120 | May 24, 2021 | Registry ↗ |
| Jul 3, 2024 | Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Ther… NCT05266586 · Dyslipidemias, High Cholesterol Obicetrapib, Ezetimibe 10mg | NAMS NewAmsterdam Pharma | Phase 2 | Completed | 119 | Aug 12, 2022 | Registry ↗ |
| Jun 5, 2024 | Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib… NCT06050291 · Healthy Volunteer Study Fixed-Dose Combination (FDC) Tablet | NAMS NewAmsterdam Pharma | Phase 1 | Completed | 28 | Apr 7, 2024 | Registry ↗ |
| Jun 4, 2024 | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular… NCT05202509 · Atherosclerotic Cardiovascular Disease Obicetrapib, Placebo | NAMS NewAmsterdam Pharma | Phase 3 | Active, not recruiting | 9,541 | Nov 2026 | Registry ↗ |
| Apr 24, 2024 | Randomized Study of Obicetrapib in Combination With Ezetimibe NCT04770389 · Dyslipidemias, High Cholesterol Obicetrapib 5mg, Ezetimibe 10mg | NAMS NewAmsterdam Pharma | Phase 2 | Completed | 112 | May 7, 2021 | Registry ↗ |
20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances